logo
logo

Vibliome Therapeutics Spins Off New Company, Raises Additional Funding

Vibliome Therapeutics Spins Off New Company, Raises Additional Funding

02/24/22, 10:15 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgbozeman
Vibliome Therapeutics, LLC, announced today that it has executed an Asset Sale and License Agreement with Beartooth Therapeutics, Inc., for two of its proprietary kinase inhibitor programs against undisclosed targets. Beartooth Therapeutics is a new company co-founded by Vibliome and Deerfield Management, which plans to finalize development candidates and advance the programs into clinical testing for oncology indications. The terms of the asset sale agreement were not disclosed.

Company Info

Company
Vibliome
Location
bozeman, montana, united states
Additional Info
Vibliome has developed a systematic approach for the development of small molecule Type-II kinase inhibitors with unique profiles and a high degree of selectivity. This platform technology is ideally suited to support emerging therapeutic approaches for cancer and other diseases where selective kinase targeting is needed. The company is based in Bozeman, Montana, and New York City. For more information or inquiries, please visit www.vibliome.com.